2023-11-13T17:14:24-06:00 2022-12-31 251622758 MAHER DUESSEL CPA'S 503 MARTINDALE STREET SUITE 600 PITTSBURGH PA 15212 990 2022-01-01 460902111 RTOG FOUNDATION INC RTOG 2157170834 50 S 16TH STREET 2800 PHILADELPHIA PA 19102 QUYNH-THU LE CHAIRMAN 2157170834 2023-11-13 1 QUYNH-THU LE 999009999 0 AMY LEWIS P01360302 4124715500 0 AAL1 IAL1 2022 2023-04-26 12:10:37Z QUYNH-THU LE 50 S 16TH STREET 2800 PHILADELPHIA PA 19102 11934766 0 X WWW.RTOG.ORG X 2012 PA TO ORGANIZE & PROVIDE FUNDING FOR MULTI-CENTER CLINICAL RESEARCH ACTIVITIES IN ONCOLOGY. 12 12 0 12 0 0 5887228 4276831 674306 7657930 1 5 0 0 6561535 11934766 0 0 0 0 0 0 0 0 0 7885522 10428486 7885522 10428486 -1323987 1506280 10342373 15118673 8486327 7097263 1856046 8021410 X THE MISSION OF RTOG FOUNDATION, INC. (RTOGF) IS TO:(1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS, (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH, (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION, (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOGF'S MEMBERSHIP IN NRG ONCOLOGY, (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOGF'S RESEARCH MISSION, (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOGF IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES, AND (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOGF RESEARCH ENTERPRISE. 0 0 8035362 7657930 RTOG'S PRIMARY PROGRAM CONSTITUTES THE FOLLOWING: (1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS, (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH, (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION, (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY, (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION, (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES, AND (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE. 8035362 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 21 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 12 12 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 0 0 0 0 0 PA X THE ORGANIZATION 2157170834 50 S 16TH STREET 2800 PHILADELPHIA PA 19102 X MITCHELL MACHTAY MD PRESIDENT & CEO 5.00 X X 0 0 0 QUYNH LE MD CHAIR 5.00 X X 0 0 0 JEFF MICHALSKI MD MBA TREASURER 1.00 X X 0 0 0 STUART WONG MD SECRETARY 1.00 X X 0 0 0 GRAHAM BURNETTE ESQ DIRECTOR 1.00 X 0 0 0 JIM DIGNAM PHD DIRECTOR 1.00 X 0 0 0 WALTER J CURRAN JR MD DIRECTOR 1.00 X 0 0 0 FELIX FENG MD DIRECTOR 1.00 X 0 0 0 LISA KACHNIC MD DIRECTOR 1.00 X 0 0 0 SETH ROSENTHAL MD DIRECTOR 1.00 X 0 0 0 MARIA WERNERWASIK MD DIRECTOR 1.00 X 0 0 0 SUE YOM MD DIRECTOR 1.00 X 0 0 0 0 0 0 0 0 0 0 RXCROSSROADS BY MCKESSON P O BOX 846025 DALLAS TX 75284 DISTRIBUTION SERVICES 252938 PRECISION BIOSERVICES INC PO BOX 715742 PHILADELPHIA PA 19171 SUPPLIES 234008 2 4254331 22500 4276831 INDUSTRY REVENUE 541700 7657930 7657930 7657930 5 5 11934766 7657930 0 5 36791 36791 40795 40795 787362 174815 612547 90 90 5506 3684 1822 1332 1332 8153 8153 SUB-AWARD RESEARCH PROJ 7585555 7585555 SITE EXPENSES 1936437 249697 1686740 POSTAGE & SHIPPING 21778 21611 167 MISCELLANEOUS 4687 4687 10428486 8035362 2393124 0 4316020 5307211 11684 9939 5113069 8667030 46667 901600 1087826 10342373 15118673 665458 3788029 7820869 3309234 8486327 7097263 X 1856046 8021410 1856046 8021410 10342373 15118673 X 1506280 4659084 0 X X 0 0 1 0 X 7310029 4992910 2684323 5887228 4276831 25151321 7310029 4992910 2684323 5887228 4276831 25151321 333559 24817762 11 14 2 1 5 33 302 269 402 973 25152327 17805236 0.98670 0.94130 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - 2018 AMOUNT: $ 302. 2019 AMOUNT: $ 269. 2020 AMOUNT: $ 402. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 INVESTMENT IN NRG ONCOLOGY 1087826 1087826 FORM 990, PART VI, SECTION A, LINE 8B NO BOARD COMMITTEES HAVE BEEN FORMED AS OF THIS TIME. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE RETURN WILL THEN BE REVIEWED BY THE SECRETARY-TREASURER AND APPROVED. THE RETURN WILL THEN BE MADE AVAILABLE FOR ALL DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, STAFF, VOLUNTEERS, CLINICAL INVESTIGATORS, AND ALL OTHERS REPRESENTING OR ACTING ON BEHALF OT RTOGF. IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST. THE DISCLOSURE IS REVIEWED BY THE RTOGF ADMINISTRATOR WITH GUIDANCE FROM RTOGF LEGAL COUNSEL. ANY INDENTIFIED FINANCIAL CONFLICT OF INTEREST (FCOI) WILL BE REVIEWED WITH THE AFFECTED INVESTIGATOR AND, IF APPLICABLE, REPORTED TO NIH WITHIN 60 DAYS OF DISCOVERY AND ACTIONS TO MANAGE, REDUCE, OR ELIMINATE THE FCOI WILL BE TAKEN BT THE ADMINISTRATOR OF THE RESEARCH ACTIVITY INVOLVED AND INCLUDED IN THE REPORT TO NATIONAL INSTITUTES OF HEALTH (NIH). MANAGEMENT OF AN IDENTIFIED FCOI WILL INCLUDE THE DEVELOPMENT AND IMPLEMENTATION OF A MANAGEMENT PLAN AND, IF NECESSARY, A RETROSPECTIVE REVIEW AND MITIGATION REPORT. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XII, LINE 3B: RTOG IS IN THE PROCESS OF COMPLETING THE REQUIRED AUDIT. FORM 990, PART XI, LINE 8: IN CONJUNCTION WITH ITS ONGOING AUDIT, RTOG REVIEWED ITS REVENUE RECOGNITION POLICY FOR ITS CLINICAL TRIALS AND IDENTIFIED VARIOUS ADJUSTMENTS THAT WERE NECESSARY TO CORRECTLY RECORD REVENUE IN ACCORDANCE WITH US GAAP. NRG ONCOLOGY FOUNDATION INC 1600 JFK BOULEVARD SUITE 1020 PHILADELPHIA PA 19103 900912747 ONCOLOGY RESEARCH SUPPORT PA 501(C)(3) LINE 7 N/A 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0